peptide protocol FAQ

Stop immediately and resume binders. Administering VIP while C4a is elevated (above 2,830 ng/mL) amplifies the existing inflammatory state because VIP modulates immune cell activity. If those cells are already activated by circulating biotoxins or persistent complement activation, the peptide enhances pro-inflammatory signaling instead of suppressing it. Patients report worsening fatigue, brain fog, joint pain, and headaches within 2–5 days of premature VIP initiation. The solution is to pause VIP, continue cholestyramine or Welchol for another 4–8 weeks, retest C4a, and only restart VIP once levels drop below 2,830 ng/mL. The peptide itself is not harmful. The timing is wrong.

Switch to a preservative-free formulation or reduce dose frequency temporarily. Some compounded VIP nasal sprays contain benzalkonium chloride or other preservatives that irritate sensitive nasal mucosa, especially in CIRS patients with multiple chemical sensitivities. Preservative-free VIP formulations are available through compounding pharmacies and eliminate this issue in most cases. If irritation persists even with preservative-free VIP, reduce dosing to twice daily for one week to allow nasal tissue adaptation, then gradually increase back to four times daily. Nasal irrigation with saline 30 minutes before VIP administration also reduces irritation by clearing mucus and hydrating tissue.

Continue for at least 30 days unless symptoms are severe. Temporary worsening is common as immune cells shift phenotype. As VIP shifts T-cell populations from Th1/Th17 to Treg dominance, there is a transient period (7–21 days) where cytokine release patterns fluctuate, causing temporary fatigue, mild headaches, or increased brain fog. This is mechanistically distinct from the cytokine surge caused by premature VIP. It reflects immune recalibration, not inflammation amplification. The key differentiator: premature VIP worsens symptoms progressively and severely; VIP-induced immune shift causes mild, transient worsening that peaks around day 10–14 and then resolves. If symptoms worsen beyond baseline severity or persist beyond 21 days, retest inflammatory markers (C4a, TGF-beta-1) to rule out missed infection or ongoing biotoxin exposure.